Lexaria Bioscience Corp. (LEXX)

Lexaria Bioscience Balance Sheet

Financials in millions USD. Fiscal year is September - August.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	1.35	5.81	10.92	1.29	1.29
Short-Term Investments	0.13	0.35	0.83	0.02	0.06
Cash & Cash Equivalents	1.48	6.16	11.75	1.31	1.35
Cash Growth	-76.01%	-47.58%	794.97%	-2.69%	-22.33%
Receivables	0.18	0.2	0.34	0.31	0.27
Inventory	0	0.04	0.03	0.12	0.13
Other Current Assets	0.5	0.58	0.32	0.18	0.07
Total Current Assets	2.15	6.98	12.44	1.93	1.82
Property, Plant & Equipment	0.42	0.37	0.46	0.61	0.59
Goodwill and Intangibles	0.46	0.49	0.36	0.29	0.27
Other Long-Term Assets	0.05	0	0	0	0
Total Long-Term Assets	0.93	0.86	0.82	0.9	0.86
Total Assets	3.08	7.83	13.27	2.83	2.68
Accounts Payable	0.24	0.15	0.11	0.15	0.18
Deferred Revenue	0	0	0	0.04	0
Current Debt	0.03	0.04	0.05	0.04	0
Other Current Liabilities	0	0	0	0	0
Total Current Liabilities	0.27	0.19	0.15	0.23	0.18
Long-Term Debt	0.14	0.01	0.05	0.12	0
Total Long-Term Liabilities	0.14	0.01	0.05	0.12	0
Total Liabilities	0.4	0.2	0.2	0.35	0.18
Total Debt	0.16	0.05	0.1	0.16	0
Debt Growth	228.01%	-48.63%	-37.66%	-	-
Retained Earnings	-45.76	-39.1	-31.83	-27.8	-23.87
Shareholders' Equity	3.04	7.95	13.27	2.53	2.38
Net Cash / Debt	1.31	6.11	11.65	1.16	1.35
Net Cash / Debt Growth	-78.50%	-47.57%	907.31%	-14.26%	-21.98%
Net Cash Per Share	0.20	1.04	2.65	0.42	0.52
Working Capital	1.88	6.78	12.29	1.7	1.63
Book Value Per Share	0.46	1.35	3.02	0.91	0.92

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).